Summary
- Failure of trial III Alzheimer drug, Solanezumab, is a major setback for Eli Lilly.
- Lilly’s spending relative to the industry is following the same pattern as in 2005 and 2007, before its stock price got cut in half in over a year.
- While Lilly is strengthening its pipeline in the diabetes space, it will not be enough to stop the stock from continuing to fall as they face stiff competition.
- Four drugs accounting for 29.6%, or almost $1.5 billion of its third-quarter sales, are due to lose their compound protection this month and next year.
To keep reading more, the article is available on Seeking Alpha. Or copy/paste: http://seekingalpha.com/article/4032921-eli-lillys-stock-price-continue-fall.